Although the clinical utility of PCSK9 levels to guide ACS treatment remains undetermined, the current study demonstrated that PCSK9 was potentially beneficial for early risk stratifications of STEMI patients, especially for diabetic patients, as the biomarker acquired the highest accuracy for predicting long-term ischemic events in the subgroup of DM. The gene discussed is PCSK9; the disease is diabetes mellitus.